Short Interest in Cocrystal Pharma, Inc. (NASDAQ:COCP) Decreases By 30.5%

Cocrystal Pharma, Inc. (NASDAQ:COCP) was the recipient of a significant decrease in short interest in the month of March. As of March 31st, there was short interest totaling 148,911 shares, a decrease of 30.5% from the March 15th total of 214,196 shares. Currently, 1.5% of the shares of the stock are sold short. Based on an average daily volume of 50,346 shares, the days-to-cover ratio is currently 3.0 days.

Insider Buying and Selling at Cocrystal Pharma

In other news, Director Phillip Md Et Al Frost purchased 50,000 shares of the firm’s stock in a transaction dated Friday, February 6th. The shares were purchased at an average price of $0.95 per share, with a total value of $47,500.00. Following the completion of the acquisition, the director owned 1,888,551 shares in the company, valued at $1,794,123.45. This trade represents a 2.72% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 28.14% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cocrystal Pharma stock. DRW Securities LLC bought a new stake in Cocrystal Pharma, Inc. (NASDAQ:COCP) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned about 0.24% of Cocrystal Pharma as of its most recent SEC filing. 6.72% of the stock is owned by institutional investors.

Cocrystal Pharma Stock Up 14.4%

COCP opened at $1.43 on Tuesday. The stock has a market cap of $19.72 million, a PE ratio of -1.81 and a beta of 1.18. Cocrystal Pharma has a 52 week low of $0.86 and a 52 week high of $2.67. The business’s fifty day simple moving average is $1.08 and its 200 day simple moving average is $1.07.

Cocrystal Pharma (NASDAQ:COCP) last released its earnings results on Tuesday, March 31st. The company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.01. As a group, equities analysts anticipate that Cocrystal Pharma will post -1.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cocrystal Pharma in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $6.00.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.